joining afternoon, us you, you thank Good for Hannah. Thank everyone, and today.
our our objectives to results this businesses. across make pleased all with progress as quarter are of our we very X continue strategic against We
to delivery, benefit system leader while the impactful in therapeutic enhance improving patients by strides and quality and advancements our as drug care costs. overall We are are life of our very making for excited we subcutaneous large-volume a health
Systems team. KORU I the and not for by All thanking them efforts shareholders want possible our is of begin without support. of to Medical our this continued their
will updates begin slides support then we to quarter. business call, over will I prepared discuss to Tom, today's update guidance. commentary. I the call XXXX Josh our the open with and ending the Tom remarks, During to turn use financials, of the concluding then will be third to our with our I After to the for up before will quarterly happy Q&A. call
across fourth quarter, The all marked third period million several milestones. quarter and company, growth of businesses. 'XX of for and QX consecutive saw performance double-digit with we strength growth our marked another growth the revenue our $X.X across strong key XX.X% of
and continued We our therapies to great see business. novel in progress momentum
by to new with yesterday entered Phase During and total III. progress drug have the X strong core programs Kira II, aided the XX clinical we indications. on-label of we underlying Phase U.S. backorder our had subcutaneous or our as the collaborations quarter, including therapy collaborations drugs sales growth of executed novel X Pharmaceuticals, were deals. now X We in and and outpaced business, XX% commercialized X XX collaboration market we on includes marketing and immunoglobulin, and drug announced SCIg, clearance. In also our This
team, margin, great off in relatively in with operations efforts On chain at small saw countries. Quarter supply up several the a XX.X% growth business manufacturing in an international X, base, from from gross and quarter by improvements improving our Our XX.X% growth ended efficiency. XX.X%, we driven
and in provide clinical Brent of product continued the confidence million Medical of a a help new build to relationships. growing our experience And therapies expertise insight Affairs, business, business million. are $XX.X finally, core and opinion Vice support key our important to well candidates by valuable our our develop with team, $XX we to our our drug and President evidence We also driven guidance leader executive his aligned pipeline, novel base advance Brent's raising Rutland. therapy is hiring range strategy, generation of to will
quarter, on enable want the I our home. to a on providing capability Before to from to moments and few spend strategy detail growing hospital the more the the shift
drug Our is system large-volume subcutaneous, or the leader in Freedom market as ml. which above we classify subcu, delivery, XX
we hospital center. their our to the use pharmaceutical system Freedom the manage companies, and homes, system The independently visit from a is monthly clear it versus system them commercialization. a our their a weekly, that to offers With to a of pathway market-proven therapies or services, value-added infusion clinic and empower or biweekly nurse-assisted attractive as is patients to
in We fully be simple, approval can a drug readiness have with and commercial countries, FDA regulatory customized SC mechanical clearance deployment. that XX rapid indications for on-label system over and X
the disposable year SC the per from The therapies reusable business growing delivered patient. core comes per to month, our FDA-cleared of pump. recurring business use comes $XXX their the per Our for start therapy market, revenue their our of consumables at this home approximately from in drug majority once and where patients our with pump are receive generating SCIg
patients PIDD, represents the leader, at therapy. therapy global on SC of opportunity, once PNH, a revenue our CIDP is infusions segment patients $XXX are who As market majority or of over IV least the we support a part globally over with per with which and XXX,XXX week. largest currently XX,XXX require This million
area drugs new business, provide moving they to clinical their market. as of formulation business product second to pharmaceutical process their drugs the and The where for IV with services, are our to subcu companies innovation SC to are working trial is introduce we our therapies a work or novel
multiple in new delivery the opportunities pharmaceutical classes or closed a X drug estimated market, total portfolio therapy multiple This novel over drug for home in and areas viability novel of phases, currently across The of diversifies therapy at FDA progress and addressable drug, pipeline. X new across represented the our identified therapies. a $X approval have has company drug large-volume billion our demonstrates an significant therapies collaborations, has and TAM. including within pipeline We XX
by market opportunity for $X.X the to the grow pipeline it We SCIg are our momentum TAM, market core number a as in excited both by supported novel growth subcu and and presents, see a of and by studies. our the business increasing to therapies for that subcu the with at-home number an We continues are of expand. continues delivery reasons delivery billion for
in has we delivery the space versus classes. benefits time, of is therapeutic adverse to First drug of further in proven levels therapeutic the benefit infections. other studies reactions are include of IV leading over which fewer therapy, Ig subcu well the been this Ig The and consistent studied seeing and
administered recent therapy; preference. patient from the supported companies multiple-drug increasing to SC showing a of for finally XX% this outside continue by XX% savings, one XX% oncology IV towards study Group therapy. numbers hospital, preference the benefits, a is pharmaceutical therapies second to study. a The And are SC with believe preference savings over the associated being We of therapeutic will that combined with drive of and UnitedHealth associated cost and patient patients cost
third new syringes our saw our commercial our we execution quarter, win to working win significant and we ensure starts, of in progress SCIg we expand prefilled strategic to are patient geographically. back Turning market, initiatives. Within
growth we continue to growth of starts, see patient SCIg the market. new the outpacing company's underlying U.S. For the
on X% XX.X% quarter services marketing just driven XX.X% for year-to-date. the by year-to-date, growth execution sales label SCIg value-added core programs, that our is is an outpacing and This market including was third and domestic and growth over Our growing expansions.
with market pump prefilled our SCIg and System, uniquely remains only fastest to FDA for Infusion prefilled the this syringe growing remains growing market, part with the capitalize the clearance a the Second, Freedom KORU indication. of on qualified market XXX(k)
the prefilled XXXX, XX.X% and has third now For overall market XXX% year-over-year market. of the of accounts the quarter for grown SCIg
markets our to several and our as pumps business Lastly, growth XX.X% both we increase ex-U.S. we grew saw in in quarter, focus our area. as continued this this consumables across European
into PFS, Given the by quarter. syringes, the or prefilled to growth want progress during driven I the deeper made being dive
above, syringe As the market is the prefilled currently segment fastest SCIg growing within the I market. mentioned
the While penetration. prefilled penetration ending stage, XXXX, clearance offer pump tripled, an opportunity. has early the third FDA vial believe their for steps only We convenience from the syringe XX.X% prefilled recent be indication Since market prefilled XX% the from study, receiving PFS the XXXX prefills format a of approximately syringe believe a of will syringe XX% the for as and with preferred of significant QX nearly a with specifically prefilled eliminates In over still continue in administration. with the quarter process. to perspective patient's satisfaction of administration, ease considered syringes reported patients we
prefilled related opportunities part with Ig elimination to the and opportunity, format. patient to of to step, a X/X Thus, a transfer in about today patient serve pursue partners vial additional total syringes While today market to of offering are satisfy XX- Prefilled syringes our pharma of we work dosing offered indications innovation X-, XX-ml requirements. to prefills the the market. according only the to and value greater continue significant due
to clinical we drug our to executing use Moving with with requirements hematology the required platform X novel in and indications to is nonrecurring drugs. companies pharmaceutical to services our collaborations with X often each yesterday. Pharmaceuticals strategy in agreements winning respiratory, and each all have novel our therapies includes made business of for our customized technical trials trials strong the SCIg neurology, use our new system includes for announced nephrology, quarter, business, this to broader This the in approval II. use devices and extend Phase and the Revenue system expanded works position leadership our and validate Kira therapy We customize to Freedom progress drug. in and we business This for in sold engineering in in drug. launch,
Phase program collaborations the a Empaveli. including drug III. total X year, Apellis' was Phase quarter XX, this Additionally, of which in brings therapy approved This novel to previous II first from to our advanced
drug We have portfolio X to our classes. total expanded
reformulations device of to approved consistent pipeline and of is new We can we globally patient-friendly want and additional regulatory making value Ig and the III them with progress to companies. pathway, non-Ig indication, Phase to has from we that provide be for also spanning specific support, quickly. an Phase We're XX are marketed and in new pharmaceutical are these Each companies drug able span collaborations training Drug the drugs. because molecules. a both to our clinic have XX a into indications that and pursuing a II represents opportunities get
by system, evidenced system Freedom needs global meet drug and the medication, adaptable to creates deliver. can quickly, as the development ability allows a design needs the of patients to these priority enter KORU the successfully flexible the using confidence of in And key to each XX,XXX-plus process. that volume clinic us Our our
additional like Now look lay take I close out at details and about to collaborations potential. closer a those would their
of an have remind I the to seeking drug's will or of these to the over collaboration X.X billion. and selling treatment expected total, on metrics, The individualized are include collaborations consider processes. TAM new consumables. potential price clinic, through total frequency a drugs ones In each everyone want The roughly average XX X our and path patients addressable dose each pump and active often specific commercialization indications population, potential Freedom and many in $X.X indications million is factors. and regulatory Before on-label and or development in that our either our include turning model an indication TAM market we patient based each they of SC how
patient As less an ASP. higher dosing example, frequent population drug a a has in II a and but of oncology XXX,XXX, expectancy the Phase
clinical drug We for the TAM have provided collaborations. risk, have our of of not phase but our each discounted
every on Our through to rely strategic plan commercialization. does to make not collaboration it
will the We on and to novel to pharma excited call pipeline However, to our strategic by remain discussion the confident therapies in update of progression patient over growth this additional quarterly will therapies' and each our indication Tom on company. goals We about are for ongoing remain novel engagement opportunity continue now potential. collaborations the pipeline. accelerate for the We our I financials. expand. a extremely show and continued plan represents to will based QX to positive track turn achieve our an that
